Atlas Trials

Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer

Clinical trial NCT05472467 · UNKNOWN

Trial details

NCT number
NCT05472467
Sponsor
Sichuan Cancer Hospital and Research Institute
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer Metastatic
Start date
2021-12-21
Primary completion
2023-12-20
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.